Exploratory secondary analysis of a phase 2b trial in 322 adults with moderate-to-severe asthma: mean eosinophils changed by -30 and -97 cells/μL with rademikibart 150 and 300 mg vs -23 with placebo at week 24; counts >1,500 cells/μL were rare in all groups.
Secondary analysisn = 322
Wechsler et al. Eosinophil Counts in Adults With Asthma Treated with Anti-IL-4Rα Rademikibart: Exploratory Analyses in a Randomized Trial